Lead Targeted Therapeutic

TransCode’s scientific co-founders discovered that metastatic tumor cells cannot survive without the overexpression of a specific non-coding RNA molecule, microRNA-10b, which regulates the viability of metastatic tumor cells.

Against this conceptual framework, TransCode has designed the first known cancer therapeutic, TTX-MC138, that efficiently inhibits microRNA-10b in metastatic tumor cells, resulting in the complete regression of established metastases with no recurrence and no toxicity. The patented technology representing microRNA-10b therapeutics, and a companion biomarker test for non-invasive detection of microRNA activity, is licensed from Massachusetts General Hospital.


INHIBITING microRNA-10b WITH TTX-MC138

TTX-MC138 deactivating microRNA-10b Click image to enlarge


Click image to enlarge
  • TransCode’s initial target, microRNA-10b, is the master regulator for the survival of metastatic tumor cells
  • Inhibition of microRNA-10b leads to metastatic tumor cell death
  • TransCode has created a platform of targeted therapeutics addressing multiple metastatic tumor types

The choice of microRNA-10b as a target is further supported by its potentially broad relevance to cancer. To date, more than 400 studies have been completed on the link between microRNA-10b and Cancer, and more than 120 studies linking microRNA-10b and Metastasis encompassing at least 18 different cancer types, including breast, pancreatic, lung, colorectal, gastric, melanoma, ovarian, hepatocellular cancer and others. These studies provide incontrovertible evidence of the critical role played by microRNA-10b in metastasis and suggest that the described approach can be broadly applicable to metastatic disease.
targeting metastatic cancers Click image to enlarge